Suppr超能文献

在使用尼替西农治疗的黑尿症患者中,比较角膜病变组与无角膜病变组以及不同性别之间的苯丙氨酸/酪氨酸途径及相关因素。

Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment.

作者信息

Ranganath Lakshminarayan R, Milan Anna M, Hughes Andrew T, Davison Andrew S, Khedr Milad, Imrich Richard, Rudebeck Mattias, Olsson Birgitta, Norman Brendan P, Bou-Gharios George, Gallagher James A

机构信息

Departments of Clinical Biochemistry and Metabolic Medicine, Liverpool University Hospitals NHS Foundation Trusts, Liverpool L7 8XP, UK.

William Henry Duncan Building, Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L69 3BX, UK.

出版信息

Metabolites. 2022 Aug 22;12(8):772. doi: 10.3390/metabo12080772.

Abstract

Nitisinone (NIT) causes tyrosinaemia and corneal keratopathy (KP), especially in men. However, the adaptation within the phenylalanine (PHE)/tyrosine (TYR) catabolic pathway during KP is not understood. The objective of this study is to assess potential differences in the PHE/TYR pathway during KP and the influence of gender in NIT-induced tyrosinaemia in alkaptonuria (AKU). Samples of serum and 24 h urine collected from patients treated with NIT during a 4-year randomized study in NIT vs. no-treatment controls (SONIA 2; Suitability Of Nitisinone In Alkaptonuria 2; EudraCT no. 2013-001633-41) at months 3 (V2), 12 (V3), 24 (V4), 36 (V5) and 48 (V6) were included in these analyses. Homogentisic acid (HGA), TYR, PHE, hydroxyphenylpyruvate (HPPA), hydroxyphenyllactate (HPLA) and sNIT were analysed at all time-points in serum and urine in the NIT-group. All statistical analyses were post hoc. Keratopathy occurred in 10 out of 69 AKU patients, eight of them male. Thirty-five sampling points (serum and 24 h urine) were analysed in patients experiencing KP and 272 in those with no-KP (NKP) during NIT therapy. The KP group had a lower HPLA/TYR ratio and a higher TYR/PHE ratio compared with the NKP group (p < 0.05 for both). There were 24, 45, 100 and 207 sampling points (serum and 24 h urine) in the NIT group which were pre-NIT female, pre-NIT male, NIT female and NIT male, respectively. The PHE/TYR ratio and the HPLA/TYR ratio were lower in males (p < 0.001 and p < 0.01, respectively). In the KP group and in the male group during NIT therapy, adaptive responses to minimise TYR formation were impaired compared to NKP group and females, respectively.

摘要

尼替西农(NIT)会引发酪氨酸血症和角膜病变(KP),尤其是在男性中。然而,在角膜病变期间苯丙氨酸(PHE)/酪氨酸(TYR)分解代谢途径中的适应性变化尚不清楚。本研究的目的是评估角膜病变期间PHE/TYR途径的潜在差异以及性别对NIT诱导的尿黑酸尿症(AKU)患者酪氨酸血症的影响。在一项为期4年的随机研究中,将接受NIT治疗的患者与未治疗的对照组(SONIA 2;尼替西农在尿黑酸尿症中的适用性2;欧洲临床试验注册号2013 - 001633 - 41)进行比较,在第3个月(V2)、12个月(V3)、24个月(V4)、36个月(V5)和48个月(V6)收集血清和24小时尿液样本进行分析。在NIT组中,对血清和尿液中的所有时间点的尿黑酸(HGA)、TYR、PHE、对羟基苯丙酮酸(HPPA)、对羟基苯乳酸(HPLA)和sNIT进行分析。所有统计分析均为事后分析。69例AKU患者中有10例出现角膜病变,其中8例为男性。在NIT治疗期间,对出现角膜病变的患者的35个采样点(血清和24小时尿液)以及未出现角膜病变(NKP)的患者的272个采样点进行了分析。与NKP组相比,角膜病变组的HPLA/TYR比值较低,TYR/PHE比值较高(两者p均<0.05)。在NIT组中,分别有24、45、100和207个采样点(血清和24小时尿液)来自NIT治疗前的女性、NIT治疗前的男性、NIT治疗后的女性和NIT治疗后的男性。男性的PHE/TYR比值和HPLA/TYR比值较低(分别为p<0.001和p<0.01)。与NKP组和女性相比,在角膜病变组和NIT治疗期间的男性组中,使TYR生成最小化的适应性反应受损。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c9e/9416442/331a3c62478d/metabolites-12-00772-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验